SCHEMBL6960302

SCHEMBL6960302

Cc1ccc(S(=O)(=O)OCCCc2ccc(N(C)C)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.48
ALDH1A1 P00352 8/20 0.44
MAPT P10636 3/20 0.44
LMNA P02545 1/20 0.44
MAPK1 P28482 1/20 0.44
GFER P55789 1/20 0.44
MCL1 Q07820 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA9 Q16790 3/20 0.42
CA12 O43570 2/20 0.42
CA4 P22748 1/20 0.42
POLB P06746 1/20 0.42
TSHR P16473 1/20 0.42
PSMD10 O75832 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
PPARG P37231 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6797730 0.92 CNR2 (0.50) CNR2ALDH1A1MAPTLMNAMAPK1
SCHEMBL18934371 0.90 ALDH1A1 (0.47) CNR2ALDH1A1LMNACA1CA2
SCHEMBL2567795 0.90 ALDH1A1 (0.47) CNR2ALDH1A1LMNACA1CA2
SCHEMBL18926560 0.85 GAA (0.50) CNR2ALDH1A1MAPTLMNACA1
SCHEMBL6961246 0.84 CNR2 (0.41) CNR2CA1CA9CA12PSMD10
SCHEMBL18926554 0.84 CA2 (0.53) CNR2ALDH1A1LMNACA1CA2
SCHEMBL7723972 0.83 CNR2 (0.54) CNR2ALDH1A1MAPTLMNATSHR
SCHEMBL4793354 0.83 FKBP1A (0.52) CNR2ALDH1A1MAPTCA1CA2
SCHEMBL7028389 0.82 CNR2 (0.50) CNR2ALDH1A1LMNACA1CA2
SCHEMBL16667873 0.82 CNR2 (0.52) CNR2ALDH1A1MAPTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6562808-B1 Calcium channel antagonists effective in treating intestinal diseases caused by abnormal acceleration of the contraction of intestinal tracts such as irritable bowel syndrome, without significant cardiac effects AJINOMOTO CO., INC. (JP) 2003-05-13 US disclosed
EP-1020466-B1 5,11-DIHYDRODIBENZ[b,e][1,4]OXAZEPINE DERIVATIVES AND MEDICINAL COMPOSITION CONTAINING THE SAME AJINOMOTO KK (JP) 2003-02-19 EP disclosed
EP-1020466-A1 5,11-DIHYDRODIBENZ[b,e][1,4]OXAZEPINE DERIVATIVES AND MEDICINAL COMPOSITION CONTAINING THE SAME Ajinomoto Co., Inc. (JP) 2000-07-19 EP disclosed